Serving hundreds of leading biopharmaceutical companies globally:

Generated: November 16, 2018

DrugPatentWatch Database Preview

Gemini Labs Llc Company Profile

« Back to Dashboard

What is the competitive landscape for GEMINI LABS LLC, and what generic and branded alternatives to GEMINI LABS LLC drugs are available?

GEMINI LABS LLC has two approved drugs.

Summary for Gemini Labs Llc

US Patents:	0
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Gemini Labs Llc

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-001	Dec 22, 1997	AB	RX	Yes	No		➤ Sign Up				➤ Sign Up
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-002	Nov 5, 2001		DISCN	Yes	No		➤ Sign Up				➤ Sign Up
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-003	Dec 22, 1997	AB	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-002	Dec 22, 1997	AB	RX	Yes	No		➤ Sign Up				➤ Sign Up
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for Gemini Labs Llc

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-002	Nov 5, 2001	6,090,799	➤ Sign Up
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-003	Dec 22, 1997	4,873,080	➤ Sign Up
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-003	Dec 22, 1997	5,312,924	➤ Sign Up
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-002	Dec 22, 1997	5,216,167	➤ Sign Up
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-001	Approved Prior to Jan 1, 1982	5,872,147	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for GEMINI LABS LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	2.5 mg and 10 mg	➤ Subscribe	2006-06-19
➤ Subscribe	Tablets	0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-02-10

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Gemini Labs Llc

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health

Moodys

Daiichi Sankyo

Healthtrust

Accenture

Baxter

Chinese Patent Office

Cantor Fitzgerald

US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.